Octreotide acetate in microspheres

DRUG4 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

Diabetic Retinopathy

Phase 3

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

CompletedNCT00130845

NovartisDiabetic Retinopathy

Start: 2000-02-29End: 2005-12-31Updated: 2011-11-17

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

CompletedNCT00131144

NovartisDiabetic Retinopathy

Start: 1999-11-30End: 2005-12-31Updated: 2011-11-17

Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

TerminatedNCT00248131

Novartis PharmaceuticalsDiabetic Retinopathy

Start: 2005-11-30End: 2006-07-31Target: 260Updated: 2012-04-10

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

TerminatedNCT00248157

Novartis PharmaceuticalsDiabetic Retinopathy

Start: 2005-11-30End: 2006-05-31Updated: 2012-05-01

Related Papers

Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies.

2017-11-077 citations